RT Journal Article
SR Electronic
T1 Outpatient regimens to reduce COVID-19 hospitalizations: a systematic review and meta-analysis of randomized controlled trials
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.05.24.22275478
DO 10.1101/2022.05.24.22275478
A1 Sullivan, David J.
A1 Focosi, Daniele
A1 Hanley, Daniel
A1 Cruciani, Mario
A1 Franchini, Massimo
A1 Ou, Jiangda
A1 Casadevall, Arturo
A1 Paneth, Nigel
YR 2022
UL http://medrxiv.org/content/early/2022/11/11/2022.05.24.22275478.abstract
AB During pandemics, out-of-hospital treatments reduce the health system burden. Controversies persist regarding the best treatment options for COVID-19 outpatients at risk for hospitalization. We assembled data from 47 randomized controlled trials investigating 51 distinct interventions in more than 60,000 outpatients until October 2022 with the endpoint of hospitalization. These trials, largely performed in unvaccinated cohorts during pre-Omicron waves, mostly targeted populations with at least one risk factor for COVID-19 hospitalization. Grouping by class, the COVID-19 convalescent plasma (CCP) (OR=0.69 [95% CI=0.53 to 0.9]), anti-Spike monoclonal antibodies (OR=0.32 [95% CI=0.24-0.42]) and small molecule antivirals (OR=0.57 [95% CI=0.3-1.09]) each had comparable efficacy for hospital relative risk reduction dependent on intervention dose and timing. Repurposed drugs had lower efficacy. The recent Omicron sublineages (XBB and BQ.1.1) in vitro resistance to monoclonal antibodies suggests a pressing need to reevaluate CCP recommendations for COVID-19 outpatients at risk for hospitalization, especially in constrained medical resource settings.Competing Interest StatementDS, DFH, AC were investigators in the CSSC-004 study; D.F. and M.F. were investigators in the TSUNAMI RCT of CCP. DJS reports AliquantumRx Founder and Board member with stock options (macrolide for malaria), Hemex Health malaria diagnostics consulting and royalties for malaria diagnostic test control standards to Alere-all outside of submitted work. AC reports being part of the scientific advisory board of SabTherapeutics and has received personal fees from Ortho Diagnostics, outside of the submitted work. All other authors report no relevant disclosures.Funding StatementThis study was supported by the U.S. Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), in collaboration with the Defense Health Agency (DHA) (contract number: W911QY2090012) (DS, AC, DH), with additional support from Bloomberg Philanthropies, State of Maryland, the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases 3R01AI152078-01S1 (DS, AC), NIH National Center for Advancing Translational Sciences U24TR001609-S3 and UL1TR003098 (DH).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:We assembled outpatient COVID-19 RCTs with hospitalization as the primary outcome, by searching MEDLINE (through PubMed), medRxiv and bioRxiv databases for the period of March 2020, to April 2022 inclusive, with English language as the only restriction. We also screened the reference list of reviewed articles for additional studies not captured in our initial literature search. We included only RCTs dealing with antiviral agents (either intentional or repurposed), and excluded supportive treatments (e.g.: antihypertensive, anticoagulants, anti-inflammatory drugs). We also excluded case reports, case series, non-randomized trials, review articles, meta-analyses and original research articles reporting only aggregate data.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDatasets used for this systematic review are publicly available in PubMed, medRxiv and bioRxiv.CCPCOVID-19 convalescent plasmamAbmonoclonal antibodyRCTrandomized controlled trialVOCvariant of concern.